Abstract
Adalimumab is a type of drug known as a biologic used for chronic inflammatory diseases, such as Crohn’s. In these medical conditions, a protein called TNF is overproduced in the affected part of the body, which causes inflammation and damage. Adalimumab blocks the action of TNF to reduce this inflammation. The FDA defines a biosimilar as a biological product that is highly similar to and has no clinically meaningful differences in safety and effectiveness to an existing FDA-approved reference product. This means that there are more treatment options for chronically ill patients at a potentially lower cost. BI 695501 is an adalimumab biosimilar that has already demonstrated similar efficacy, safety and immunogenicity to adalimumab reference product in patients with chronic plaque psoriasis and rheumatoid arthritis. In this video, Professor Stephen Hanauer discusses the VOLTAIRE-CD study, which aimed to compare the safety and efficacy of the BI 695501 biosimilar in Crohn’s disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
